SWM
FOLD

Spire Wealth Management’s Amicus Therapeutics FOLD Stock Holding History

Spire Wealth Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,723
Closed -$14.1K – 2439
2025
Q1 		$14.1K Hold
1,723
– – ﹤0.01% 1727
2024
Q4 		$16.2K Buy
1,723
+150
+10% +$1.56K ﹤0.01% 1689
2024
Q3 		$16.8K Buy
+1,573
New +$17.1K ﹤0.01% 1486
2022
Q1 		– Sell
-842
Closed -$10K – 2650
2021
Q4 		$10K Buy
+842
New +$9.38K ﹤0.01% 2373
2021
Q2 		– Sell
-599
Closed -$6K – 2711
2021
Q1 		$6K Buy
+599
New +$9.27K ﹤0.01% 2564

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Spire Wealth Management's FOLD Position: Q2 2025 in Review

Spire Wealth Management sold out of Amicus Therapeutics (FOLD) in Q2 2025, closing a stake of 1,723 shares — an estimated $14.1K sold.

Spire Wealth Management first reported a position in FOLD in Q1 2021 and held it in 5 quarters. The position peaked at $16.8K in Q3 2024. 272 funds tracked by Wall St. Rank hold FOLD as of Q2 2025.

  • Spire Wealth Management reported no remaining Amicus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Spire Wealth Management sold 1,723 Amicus Therapeutics shares in Q2 2025, an estimated $14.1K.
  • Spire Wealth Management first reported a position in Amicus Therapeutics in Q1 2021 and held it in 5 quarters.
  • Spire Wealth Management's Amicus Therapeutics position peaked at $16.8K in Q3 2024.
  • 272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2025.

Based on Spire Wealth Management's 13F filing for Q2 2025, filed 4 Aug 2025.